Key Points
- Elanco CFO Robert Vanhimbergen bought 4,200 shares at an average price of $23.08, investing $96,936 and increasing his ownership by 3.15% to 137,516 shares.
- Elanco reported quarterly EPS of $0.34, beating estimates of $0.27, while revenue reached $1.37 billion and rose 10.2% year over year. The company issued full-year 2026 EPS guidance of $1.10–$1.16.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $29.09 versus the stock’s reported $22.26 opening price.
Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) CFO Robert Vanhimbergen purchased 4,200 shares of Elanco Animal Health stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the acquisition, the chief financial officer owned 137,516 shares of the company's stock, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Elanco Animal Health Price Performance
ELAN opened at $22.26 on Tuesday. The business has a fifty day moving average of $24.67 and a 200 day moving average of $24.07. Elanco Animal Health Incorporated has a 52-week low of $16.89 and a 52-week high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The stock has a market cap of $11.12 billion, a P/E ratio of -54.29, a PEG ratio of 1.32 and a beta of 1.67.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the company posted $0.26 EPS. Elanco Animal Health's quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.
Hedge Funds Weigh In On Elanco Animal Health
Several institutional investors and hedge funds have recently bought and sold shares of ELAN. Great Lakes Advisors LLC acquired a new position in shares of Elanco Animal Health during the second quarter worth $6,047,000. Danske Bank A S acquired a new stake in shares of Elanco Animal Health in the 2nd quarter worth $14,348,000. First National Bank of Omaha acquired a new stake in shares of Elanco Animal Health in the 2nd quarter worth $3,974,000. Meeder Advisory Services Inc. purchased a new position in Elanco Animal Health during the 2nd quarter worth $261,000. Finally, BlackRock Inc. purchased a new position in Elanco Animal Health during the 2nd quarter worth $1,202,198,000. 97.48% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Piper Sandler reiterated an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, May 7th. Morgan Stanley raised their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 22nd. Wall Street Zen downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Sunday, May 24th. Finally, TD Cowen boosted their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.09.
Check Out Our Latest Report on Elanco Animal Health
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
